 |
|
|
| |
Pharmacokinetic (PK) Modelling and Simulation to Support Weight-Based Dosing of Maraviroc (MVC) in Pediatric Subjects When Co-administered With Potent CYP3A Inhibitors
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France
McFadyen L,1Weatherley B,1Chan PLS,1 Vourvahis M,2Moore K,3Marshall SF1
1Pfizer, Pharmacometrics, Sandwich, UK; 2Pfizer, Clinical Pharmacology, New York, NY, USA; 3ViiV Healthcare, Clinical Pharmacology, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
